The 10 Most Recommended Pharma & Life Sciences Solution providers in 2019

The

VOL 04

April 2019

ISSUE 01

10 Most Recommended Pharma & Life Sciences

Solution providers in 2019

S arjen Systems Promoting Indian Pharma Research on Global Scene

Nikur Mody Founder

From The

Editor RAPIDLY EVOLVING INDUSTRY PHARMA & LIFE SCIENCE THE OUTLOOK

A

decade ago, the global industry of pharma and life science, which was of 390 billion USD, has now crossed 1 trillion USD and still it is marching forward majestically.

“One of the biggest challenges to medicine is the incorporation of information technology in our practices” said Samuel Wilson.

Today, to remain competitive in this dynamic environment, the Pharma and Life Sciences organizations are quickly adapting and responding to the on-going changes in market conditions, customer requirements, and government and industry regulations. The giant companies are controlling the one-third of the market and producing revenue around in billions of USD, while many large numbers of start-ups and SMBs are competing to get their share of pie, and benchmark their existence in this fiercely competitive domain.

Predicting the future for better analysis of patient adherence and improving time to market remains the key element of success.

Accessing, analysing and managing the vast volumes of data have been a very critical task to pharma and life sciences companies, as they improve business efficiency and performance.

And, this is where this ‘Next Generation’ architecture the Big Data and Analytics are helping to improve the efficiency and the development processes.

On the concluding note, today the world is leveraging technology intelligently to gain competitive advantage. The profound market research is done in order to provide a plethora of solutions. With changing times, the industry is uncovering innovations that are revolutionizing the current product lines and unfolding infinite opportunities for betterment of the manking.

ambhale

Shruti P. J

Shruti P. Jambhale

C o n

Cover Story 10

Sarjen Systems Promoting Indian Pharma Research on Global Scene

cxo 24

Interview With Insights Success

18

Digitalizing Pharma

5 ways in which Digitalization is Transforming Healthcare and Pharma Industry

32 Accurex Biomedical Pioneer in Manufacturing and Marketing of In-vitro Diagnostic Reagents

Healthcare Predictions

Future Predictions of Electronic Health Records, 2019 and Beyond

t e n s Ashish Life Science Delivering Highest Quality Veterinary Medicines at Economical Price

Fermenta Biotech Ltd Discover | Develop | Deliver

Nucleome Informatics Unraveling the Genomes for a Better Future

Articles

22

30

38

26

34

Medicine World Insights

Pharma Trends

10 Medicines that Changed the World

Top Pharmaceutical Trends to Watch Out in 2019

C o n t e n s

Editor-in-Chief Pooja M. Bansal Managing Editor Devasish Kanojiya Executive Editor Shruti P. Jambhale Art & Design Head Amol Kamble Associate Designer Poonam Art & Picture Editor Rahul Kavnekar Co-designer Mayur Koli

Business Development Manager Akansha Garewal Sales Executives Rutuja, Kaustubh, Shraddha, Joan

Technical Specialist Amar, Pratiksha Digital Marketing Manager Prashant Chevale SME-SMO Executives Swati, Manoj Circulation Manager Tanaji sales@insightssuccess.com

April, 2019 Corporate Ofď€ ces: Insights Success Media and Technology Pvt. Ltd. th

Off. No. 513 & 510, 5 Flr., Rainbow Plaza, Shivar Chowk, Pimple Saudagar, Pune, Maharashtra 411017 Phone - India: +91 7410079881/ 82/ 83/ 84/ 85 Email: info@insightssuccess.in For Subscription: www.insightssuccess.in

Insights Success Media Tech LLC 555 Metro Place North, Suite 100, Dublin, OH 43017, United States Phone - (614)-602-1754 Email: info@insightssuccess.com For Subscription: www.insightssuccess.com

Cover Price : RS. 150/Follow us on :

www.facebook.com/insightssuccess/

https://twitter.com/insightssuccess

Copyright Š 2019 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights Success Media and Technology Pvt. Ltd. Reprint rights remain solely with Insights Success. Printed and Published by Insights Success Media and Technology Pvt. Ltd. RNI NUMBER: MAHENG/2018/75953

1 T H E

MOST RECOMMENDED

PHARMA&

L FE SCIENCES SOLUTION PROVIDERS IN 2019

P

harma and life sciences companies are taking important steps to advance their business processes and drive greater efficiencies.

The industry will embrace transformation initiatives at a faster pace in coming years, across multiple functional areas, including commercial, clinical, regulatory, and quality.

In product development, companies are focused on streamlining end-to-end processes to speed time to market and maintain compliance.

For commercial teams, driving smarter engagement with customers remains a core focus as they launch more specialized products.

This month, Insights Success has come up with a very contemporary topic and has dealt under the issue of “The 10 Most Recommended Pharma & Life Sciences Solution providers in 2019”. Here we have tried to focus on the different business portfolios with unique service solutions, and Sarjen Systems Pvt. Ltd. has grabbed our attention most to become the Cover story of this magazine. This brand is one of the best when comes to the Pharma and Life Science Solution Providers.

A Look into the Pharma & Life Science Canvas

We have also focused on different companies those have come up with unique solutions. Ashish Life Science Pvt Ltd offers a range of cutting –edge veterinary products with the world-class manufacturing infrastructure and relationship driven approach. Fermenta Biotech Limited is a multifaceted organization with a high degree of focus on research, development and product delivery in the field of biotechnology, pharmaceutical and environmental solutions. Nucleome Informatics Private Limited plays a major role by providing Genomics and Bioinformatics analysis support.

Alongside, the companies like Avesthagen Limited, Global Calcium Private Limited, Infionic Inc., Kare4u Healthcare Solutions Pvt., NecLife, Syngene have also been featured in the listing of “The 10 Most Recommended Pharma & Life Sciences Solution providers in 2019”.

The interview with Insights Success, Abhinav Thakur gave us glimpses on his brand Accurex Biomedical Pvt. Ltd. It is one of the top 3 manufacturers of quality Clinical Chemistry Reagents and Urinanalysis Test Strips with over 34 years of expertise in this area.

This magazine also includes leaders’ thoughts as well. Sudip Chhatui, the VP- Business and Operations discuss on the “5 ways in which digital is transforming healthcare and Pharma industry” and Kumar Subramaniam, the Founder & CEO of 75Health highlights on the “Future Predictions of Electronic Health Records, 2019 and Beyond”.

The editor’s thoughts are also part of this magazine where they have researched on contemporary topics like Top Pharmaceutical Trends to Watch Out in 2019 and 10 Medicines that Changed the World.

So have a look at the magazine and get the Insights of the Pharma and Life Science Solutions!

1 T H E

MOST RECOMMENDED

PHARMA&

L FE SCIENCES SOLUTION PROVIDERS IN 2019

S arjen Systems Promoting Indian Pharma Research on Global Scene

COVER STORY

Nikur Mody Founder

T

oday, everyone is well aware that Pharma Research is the sector where there are only a few predominant players. There are many companies, which are embracing the changes and creating a niche in the pharma & life science sector. Sarjen Systems is one such company which is providing affordable solutions by supporting and promoting pharma research – a small step to bring Indian pharma and pharma research on the global scene.

With the Vision of “Having a world-class organization with operational excellence and global reach”, Sarjen Systems has always maintained standards to excel with minimum fuss following on the Mission of “Spreading the power of business technology solutions to customers across the globe; adding value to their businesses. And, encouraging support for our employees who in turn would provide exceptional service to the customers”.

The Outset of the Sarjen Systems Nikur Mody is the Founder of Sarjen Systems and ever since, he has always been interested to strike out, pursuing that seed of an idea with a zealous rage. Coming from an IT background, his interests led him to think of introducing simplified approach to software development.

In 90s, a lot of business software were entering into the market and gaining momentum to get recognized. By the time, Mody realized that there were ongoing gaps between business expectations and technology enthusiasts who would understand those expectations very differently.

And, amazingly, Sarjen Systems was a result of this ideology and was founded in the late 90s to offer technology

‘DEVELOPING ‘SOLUTIONS USING CUTTING-EDGE

TECHNOLOGY

&

STRETCHING

THE LIMITS TO GET THE BEST solutions understanding and serving precise business expectations.

It became easier for Sarjen Systems, to meticulously study customer processes, variations in them from customer-tocustomer, and employ a dedicated team of business technology consultants. Its primary function is to fulfill customer expectations and deliver that last-mile customization to achieve significant improvement in work efficiency.

Leader, Motivator, and a Mentor Nikur Mody is a visionary, at the nucleus of the team of brilliant experts, guiding and providing directions to the organization through the emerging industry and technology changes and evolving methodologies. This has

helped Sarjen Systems start the next “great big” walk, playing a key role in shaping the corporate functions of business development as well as finance.

Nikur has completed an MBA in International Business and Finance after finishing his Bachelor’s in Engineering with specialization in Computer Technology. His innovative but practical approach has helped Sarjen Systems’ customers to realize value proposition through software solutions. Having worked with all functional areas at grass root level, has helped in envisioning innovative projects with great detail. Prior to Sarjen Systems, he has worked with IT companies like L&T Information Technology and Mastek Ltd. in

strategic planning where he engaged his technology and engineering skills to solve significant corporate challenges.

Notable Software Solutions Since its founding, Sarjen Systems has stood out through its own unique business style. And, has been known to architect, design and develop proprietary technology stack with enormous careful thought and consideration.

The product story includes three flagship products which are an evolution of solutions progressing to address client demands. It starts with Sarjen Systems developing PharmaNET for supply chain and sales ‘n distribution, for sales force automation – FFReporting, and then

FForce – a Field Sales Excellence platform.

Some other unique solutions are: KnowledgeNET - a global Drug dossier publishing and lifecycle management; RIMS for regulatory information management.

devices, clinical trials, veterinary vigilance – incorporated with signal detection and literature automation.

BizNET - Paperless clinical trial management which can cover several different types of trial protocols, study types.

Whereas consulting on SAP deployment, Computer System Validations (CSV), Data analytics and AI & Machine Learning (ML), extending applications as Mobility solutions are Sarjen Systems’ forte.

ProcessXE - an MES in the form of pharmaceutical manufacturing automation with eBMR, Dispensing and logbooks.

QEdge - an automated enterprise-wide quality management (eQMS) for quality processes to maintaining training records and eLearning to document control and management for controlled processes and practices.

PvEdge - Drug safety database for pharmacovigilance of drugs, vaccines,

The Plus Points Starting with the sales and distribution solution, PharmaNET and then integrated it with ERP to give a robust boost to have some vital complexities outside of ERP, Sarjen Systems kept on adding one solution after another in its

SARJEN

SYSTEMS

HAS AN AMALGAMATION

‘‘

OF TECHNOLOGY

AND INDUSTRY

KNOWLEDGE

CATERING SOLUTIONS WITH SIMPLICITY, EFFICIENCY

&

VISIBILITY TO

AN ENTERPRISE

solution list. In this broad spectrum, mobility solutions on one end and on the other end, developing and implementing solutions for digital transformation of clinical research organizations, drug safety database, enterprise-wide quality management and many more. At the core of Sarjen Systems’ solution implementation success, there is a flexible delivery approach where it efficiently merges its domain expertise with the proprietary technology stack. All the products can be easily integrated with industry

‘GREATER ‘ CONSTANT

GOALS ARE THE WAY TO KEEP

MOMENTUM

GOING AND

SUCCEED standard enterprise applications. Also, the project management and consulting teams seamlessly execute integrating of projects ensuring high throughput.

The solutioning for pharma and life science domains was the precursor of implementing processes and maintaining high quality standards with continued improvements. This would help in ensuring that there were no defects or bugs in delivery, documentation and maintaining all-around quality standards. Sarjen

Systems provides solutions and services across several industry domains including Pharmaceutical, Healthcare, Life sciences, FMCG, and few others; complying with global regulatory guidelines.

Sarjen Systems’ USP · Expertise in Pharma and Life science domains · Proprietary Technology Stack · Global Exposure/Presence · Complete solution basket – from Drug Development to Sales · Expert on cGxP and Regulatory guidelines · Solutions compliant with Part 11 (Annex 11, EMA and 21 CFR Part 11, US FDA) and global guidelines · Multiple Licensing models to suit enterprise needs Unlocked Milestones Getting ISO 9001:2008 certification was the natural progression and it gave way to very structured quality management integrated with Sarjen Systems’ SDLC. Then, upgrading to risk and opportunity based ISO 9001:2015 standards to achieve and maintain control, and continual improvement for processes, products and services. Continuing them forward ensures structure, process-driven approach for seamless quality. Also, implementing compliant GxP computerized systems using GAMP5 driven risk-based validation for part 11 compliance.

Dynamic project management with the right set of people to develop solutions using cutting-edge technology, stretching the limits to get the best, achieving timelines in the budget, rising to the challenge of defining milestones, planned commitments and

deliverables, maintaining quality, tracking progress and overall strategizing the various stages of software development is Sarjen Systems’ highlighting forte.

Rewards and Recognitions Sarjen Systems was recently shortlisted as “Best Software Company” @ Vibrant Gujarat Technology Summit.

Sarjen Systems is a Microsoft Gold partner. Also, NASSCOM and Gesia member. Their core team members have been invited to speak at numerous events on various topics. They have recently hosted a NASSCOM event.

A Piece of Advice “One must focus on deep domain expertise and user-centric design with persistence to adapt, adopt and innovate. Small and meaningful improvements will lead to hugely differentiating product in the long run.” – states Nikur Mody.

Exploring Market Leadership Sarjen Systems’ ongoing adaptation of AI, ML, Blockchain and Deep Learning has brought impactful change across its solutions. These technological advancements of now and tomorrow, would not only improve overall efficiency and inculcate good practices but also indirectly contribute to better and greater patient safety.

Sarjen Systems is all set to continue its habit of innovations by embedding new technologies and achieve a higher position as a leading software solutions provider, globally.

KNOW US BETTER • Founded Year: 1998 • Headquarter in: Ahmedabad, India • Major Operation Centers: Support offices in Mumbai, India; London, UK and Durham, USA • Total Number of Clients Served & Countries Served: 100+ clients in 50+ countries • Our Tagline: Pioneering digital transformation for Indian Pharma research • URL: www.sarjen.com

‘‘IDEA WE A WORKCULTURE FLOWS MIND EASILY

WHERE

ARE

VERY

OUT OF

CREATING

Read it First

Subscribe today Yes I would like to subscribe to Insights Success Magazine.

Global Subscription Date :

Name : Address :

Telephone : Email :

City :

State :

Zip :

Country :

Cheque should be drawn in favour of : INSIGHTS SUCCESS MEDIA AND TECH PVT. LTD.

CORPORATE OFFICE Insights Success Media and Technology Pvt. Ltd. Off No. 513 & 510, 5th Flr, Rainbow Plaza, Shivar Chowk, Pimple Saudagar, Pune, Maharashtra 411017.

Phone - India: 020- 7410079881/ 82/ 83/ 84/ 85 USA: 302-319-9947 Email: info@insightssuccess.in For Subcription: www.insightssuccess.in

Interview with Insights Success

Accurex I Biomedical

n today’s fast paced world, disease is not taken care of until body shows symptoms. Can high quality healthcare be delivered if patient’s physician is hurried, cold or uncaring? That’s why many of the companies are innovating new technologies, new processes for timely diagnosis and treatment of diseases.

INTERVIEW WITH INSIGHTS SUCCESS

Pioneer in Manufacturing and Marketing of In-vitro Diagnostic Reagents

18 |

In an interview with Insights Success, Abhinav Thakur, Managing Director at Accurex Biomedical Pvt. Ltd. has shared some insightful views and highlighted the influences made by their company. The company is one of the top 3 manufacturers of quality Clinical Chemistry Reagents and Urinanalysis Test Strips with over 34 years of expertise in this area.

1. Share with us the motivating factors that led towards the inception of company?

I was studying in the USA when unfortunately, my father passed away prematurely. I came back to India to run the company for my family.

At that point of time motivation for me was survival of the family business.

Now the motivation for me is to grow the company so I can have an impact on the economic development of our country. I strongly believe that strong economic development is the antidote the poverty.

2. Brief us about the goal, vision and mission of the company; it has set to mark its exceptionality in future.

We are in the medical diagnostics industry and impact the lives of humans. 70% of medical decisions are made based on medical diagnostic reports. Hence our mission is to help save lives by providing accurate and precise medical diagnostic solutions to pathology laboratories.

Our vision is to be one of the Top medical diagnostic companies of India by 2025.

3. Which is you flagship product? Tell us something about that. It would be great if you provide us 2-3 notable feedbacks from of renowned clients/business leaders regarding your products/services.

The most common test in any pathology lab is blood glucose. Diabetic patients are aware about their blood sugar levels and blood glucose is also checked at home by many diabetics.

If there is an error I the blood glucose report the chances of the patient questioning the report are very high when compared to other tests.

If the patient finds out the results provided by the lab are inaccurate by testing in another lab or at home, then the lab loses a customer and its reputation.

Consequently, blood glucose is one of the test on which the reputation of a lab depends.

| APRIL 2019

Abhinav Thakur MD

APRIL 2019 |

| 19

Accurex today is the largest supplier of blood glucose reagents in the country because of the quality of our reagents.

This proves that our quality of reagents is the best in the country.

4. Tell us about the services you provide through your venture (apart from your flag-ship one).

We also provide medical diagnostic instruments.

5. What is the uniqueness of your products and services as compare to your competitors? Kindly elaborate in detail.

Our company was established in 1984. Since we have been in the market for over 34 years we have build a strong brand in the market. If it was not for the quality of our products it would not have been possible for us to survive in the market for over 34 years.

Hence quality of our reagents and resulting brand for the last 34 years is our competitive advantage.

6. Brief us about the Founder/CEO of the company and the major contribution of him/her towards the development of the company.

My father, Mr. Anil Thakur was the Founder & Ex-Managing Director of Accurex Biomedical Pvt. Ltd. He was an excellent visionary. Under his leadership, Accurex had launched various innovative products and marketed them with innovative strategies.

He established Accurex as a Customer-Oriented organization, and launched the 24 x 7 module for all Accurex customers to log on their complaints/queries 24 hours a day; 7 days a week - the first-of-its-kind in India.

Mr. Thakur took Accurex to international platforms through Medica, APCCB and various other International exhibitions and conferences. His contribution towards Accurex for the last 20 years was enormous. Unfortunately, Mr. Thakur passed away on 25 January, 2004. However Accurex will continue to be guided by his ideals and vision. In the near future, Accurex will achieve a leadership position in the Asia-Pacific region which was his dream.

20 |

7. What are the positive developments going on in the Pharma & Life Sciences Solution provider company?

Point-of-care testing (POCT), or bedside testing is defined as medical diagnostic testing at or near the point of care—that is, at the time and place of patient care. This contrasts with the historical pattern in which testing was wholly or mostly confined to the medical laboratory, which entailed sending off specimens away from the point of care and then waiting hours or days to learn the results, during which time care must continue without the desired information.

POC testing is getting popular in the medical diagnostic industry.

Through POC testing the lab tests are available at the doctors and patients at home. This is convenient to the patient.

8. Your advice to budding entrepreneurs?

Four mantras: 1. Good Governance: Never compromise on your ethics. Sooner or later you will have to pay the price. Reputation built over years can be destroyed in hours if you compromise on ethics.

2. Empower your team. Don’t dictate your terms to the team but involve your team in the decision making process to get ownership.

3. Build a competitive advantage in your business or you will become a commodity soon and loose your market share. You need to keep innovating to build your competitive advantage.

4. Purpose: You need to build a strong purpose for your business. If you don’t have a strong purpose then you will give up in the difficult times. Money cannot be the only purpose because if money is the only purpose then it will be short lived and you may end up taking short cuts.

9. What the company desperately wants to achieve in the next few years?

In the next few years we want to build our foundation strong so we can raise funds and grow to achieve our mission and vision.

| APRIL 2019

Ashish Life Science Delivering Highest Quality Veterinary Medicines at Economical Price

Meet the Profound Founder Raujesh Agarrwal, the Founder of Ashish Life Science Pvt. Limited, has completed PG in Family Managed Business. He is responsible for deploying the company’s strategic vision and developing business alliances as well as building the management team. He has been actively involved in sales & marketing of the company products all over the world. Over the period of time, he appointed distribution & marketing channel in over 60 countries.

Idea behind ‘ALS’ After travelling to many countries, Raujesh realized the potential of Indian veterinary medicine. He recognized the huge business prospective for Animal health products in International markets. Seeing the vision and growth of the industry he decided to start manufacturing and exporting veterinary products.

Raujesh Agarrwal, Founder

A

shish Life Science Pvt. Ltd. (ALS) is established since 2002. Since inception, it is taking efforts to deliver significant value to its customers by understanding their needs and innovating to offer the right choice of products. Over the years, it has built up a reputation for reliability and trust between company and its customers.

ALS’s entire team is consistently evolving to meet its customers’ needs across the Globe. It offers a range of cutting –edge veterinary products with the world-class manufacturing infrastructure and relationship driven approach.

“We pride ourselves on personal service, good working relationships, and satisfying our customers wherever they may be.” says Raujesh Agarrwal, the Founder.

22 |

“We believe animals have been catering to service of mankind and it is our duty to reciprocate back.” –states Raujesh.

World-Class Quality Products The company has therefore, developed a strong focus on ‘Animal Healthcare’. The provided quality is beyond the horizon of any negotiation. Therefore, world-class manufacturing facility has been set up that could meet stringent cGMP Guidelines of any regulatory body including World Health Organization. The company strictly follows cGMP in all aspects of production and distribution activities. Also, the manufacturing facility is approved by various health authorities for supply of veterinary medicines.

Inclusive Services ALS exhibits high diligence at every level and function.

| APRIL 2019

1 T H E

MOST RECOMMENDED

PHARMA&

L FE SCIENCES SOLUTION PROVIDERS IN 2019

Adherence to quality, best-in-class manufacturing practices, highest level of laboratory certification and high service standards have enabled it to build lasting relationship across the globe.

“As India is strong on human pharmaceuticals; therefore, we saw an opportunity for pharmaceutical in the Animal space and decided to totally focus on animal products.” states Raujesh.

Rising above the Horizon Behind the meteoric rise of ALS, there is a team of committed individuals. The team of ALS comprises of dedicated professionals who believe in learning, empathy and innovation. The entire team is relentlessly and passionately working towards the advancement of animal care.

ALS operates across the entire spectrum of therapeutic segments – Antiparasitics, Ecoparasiticides, NSAIDs, Antibiotics, Antifungal, Antiprotozoal, Tonics and Neutraceuticals to name a few. Besides, it also offer all dosage forms – bolus, tablets, powder, suspensions, solutions, oral paste, injectable and spray & ointments ensuring that its clients also have an ease and effectiveness of administrations.

Notable Achievements Ashish Life Science has won the “SME Business Excellence Awards 2014”, presented by D&B, The Times Group and Federal Bank. Also, it has been recognized as “India’s small Giants” by India SME in 2014. Furthermore, Raujesh was interviewed by ET now after ALS was recognized as an emerging “Pharma Company in micro segment”.

Additionally, ALS has won the prestigious “Top 100 SMEBOI Awards” (achievers of 2012), the “Top 100 SMEBOI Awards” (Achievers of 2013) and the “ECGCD&B- Indian Exporters Excellence Awards 2015 – Best manufacturing Exporters” Award along with the Golden Maharashtra MSME’s “Manufacturing Summit 2015 Award”. And, it has been featured in the well-known “Dollar Business magazine” in 2016.

APRIL 2019 |

We believe that our customer's customer is our customer and satisfaction of these customers is our responsibility as well, and, we believe in delivering Value

Founder’s Piece of Advice “Today, there is strong awareness by people about generics. People have started questioning the cost of the product. Thus, this is forcing companies to reasonably price their products.” says Raujesh. Furthermore, he said “It’s all about Vision – Passion – Commitment”.

Rock-solid Future The company is having crystal-clear vision and thus, gearing up to adopt the future trends. It has established its name in the international market and will continue to surpass the expectations of the customer and always improve and deliver highest quality at economical price on timely basis.

| 23

Digitalizing Pharma

Author ABOUT THE

Sudip Chhatui –VP, Business and Operations at Curofy

Sudip hails from Kolkata NSIT, Delhi Alumni. He was the ďŹ rst person in the Curofy Marketing team, who joined before the launch of the Curofy app.

Initially set up and led the growth team and is now leading the Business development team Curofy.

He is a startup enthusiast.

And, he is one who loves traveling. Also, a Real Madrid fan.

24 |

| APRIL 2019

5

WAYS IN WHICH DIGITALIZATION IS TRANSFORMING HEALTHCARE AND PHARMA INDUSTRY

T

echnology is changing every industry in significant ways. No one can dispute technology’s ability to enable us all to live longer and healthier lives.

From surgical robots to “smart hospitals,” the digital transformation is revolutionizing pharma and healthcare industry.

While talking about digitalization, a point which needs to be clarified is that it isn’t just about automation of process or job or even new technology. It is much bigger and more fundamental than that. Digital transformation is about using digital technologies and data to fulfil the need of the consumer.

Data visualization to increase accessibility Data visualization isn’t just any art, it’s grounded in real results and industry findings. With the new technology, the way people access and process information are changing.

For example, smart health monitors that can collect personalized, real-time data, encouraging healthier lifestyles help in gathering more lifestyle data, and medical records. Comparing the responses of patients with similarities in DNA, medical histories and lifestyle can allow us to understand health risks and the impact of different treatments. This sharing of data-based intelligence if done in a tangible and accessible way, not just helps the scientifically-minded people but also helps the border audience.

Financial transparency: Technology helps people in getting information about healthcare expenses. Till now, if the patient was getting treated, it was often unclear whether the procedures being done are actually necessary or not. But, now the patients and their family are well aware of the treatments. There’s also a lack of consistency for health care treatments, the same services and procedures vary in cost from state to state, sometimes even from one hospital to the next. In many cases, patients don’t know how much a procedure costs until it’s done and they’ve received the bill.

Healthcare cost sometimes leads to personal bankruptcy.

Digital transformation is helping the system to improve the overall patient experience.

Digitalization streamlines the process for efficiency: Future-forward technologies like AI that can make some of the major complex kind of decisions using in-depth data and analytical calculations are transforming strategic processes as we know them.

Increasing channel of communication:

Access to a wide range of medical products

Earlier if a patient had any healthcare concerns they used to rush to the hospital. However, with a growing digital presence, patients now explore the internet for hospital sites, e-mailers to connect to the doctor. Other than this, patients have online access to medical records which they can share with their doctors.

The medical product information is easily accessiable nowadays, it is no more limited to pathways of pharma companies and the secrecy no longer exists. Information about every medicinal product is available on the internet.

Patients and consumers can easily find various ways to cure there condition through the internet. They can even find the alternatives to drugs without spending a penny.

Digital transformation is an ongoing journey that requires putting the consumer at the centre of your business. It has created a whole new realm of possibility for the consumer, specifically with the advent of smartphones and their applications (apps). Smartphone apps are now considered helpful in enhancing patient education, facilitating communication and patient engagement.

APRIL 2019 |

| 25

Medicine World Insights

Penicillin

01

10

Medicines that Changed

the World

It was discovered in 1928 by Scottish scientist Alexander Fleming. Antibiotic, People began using in 1942 to treat infections and it is used to treat infections caused by certain susceptible bacteria.

02 Ether/General Anesthesia

03

The use of anaesthesia can be traced back to ancient civilizations when opium and other natural substances were used for the purpose. The first public demonstration of the use of Ether as an anaesthetic was done in 1846 by William T.G. Morton. Diethyl Ether or Ether is an organic compound holding anaesthetic properties and was widely used during surgeries until 2005.

A natural protein, it needs to be administered as medicine for diabetic patients. First used in 1922

by Frederick Banting, Charles Best and James Collip. It is used to treat diabetes and complications arising due to it and used along with glucose to treat high blood potassium levels.

05 Oral Contraceptives

Aspirin

04

Oral Contraceptive pills are a method of hormonal contraception for birth control taken by women. In 1950 Margaret Sanger jotted down her research findings to develop a birth control pill and in 1960, the first pill was approved. Some pills contain both estrogen and progestin while some contain only progestin. They prevent fertilization by inhibiting ovulation and thickening cervical mucus and depend on the user's adherence to the dosage.

26 |

Insulin

A non-steroidal anti-inflammatory drug, acetylsalicylic acid (ASA) was first created in 1853

by French Chemist Charles Frédéric Gerhardt and rechristened as Aspirin by Bayer for commercial use. It is used to treat pain, fever and inflammation in general and used specifically in case of heart attacks, and certain types of cancer.

| APRIL 2019

Mechlorethamine

06

Also known as Chlormethine and HN2 is a cytotoxic chemotherapy agent derived from mustard gas. Once used in warfare, their medical utility was first established by a team led by Cornelius P. Rhoads. Its derivatives are used to treat cancer and lymphoid malignancies like Hodgkin's disease, prostate cancer and leukaemia.

Chlorpromazine

08

It was discovered in 1950 by chemist Paul Charpentier and was later produced as the first antipsychotic medicine. Commonly marketed under the name of Thorazine it is used to treat psychotic disorders like schizophrenia, Bipolar disorder among others.

Antiretroviral

10

Multiple Antiretroviral Medicines are used to manage HIV/AIDS during the Antiretroviral Therapy. Taken in combination, these drugs prevent the growth of the virus to slow down and control the disease. The therapy first started as a solution to the dreaded disease in 1996.

APRIL 2019 |

07

Morphine

A pain medication extracted from plants which belong to the opiate family. First isolated during the years 1803-1805 by Friedrich Serturner and commercially available in 1827. It acts on the central nervous system (CNS) to suppress the feeling of pain and is used to treat chronic, acute, myocardial and labour pain and can be administered orally or injected.

09

Statins

Statins are a class of lipid-lowering medicines that effectively reduce LDL cholesterol.

Commonly sold as atorvastatin under the trade name Lipitor among others, it was first isolated by biochemist Akira Endo and approved for medical use in 1996. It is used to prevent cardiovascular diseases and abnormal lipid levels.

Sneha Sinha Editor

| 27

Fermenta Biotech Ltd Discover | Develop | Deliver Himachal Pradesh and was followed by another in 2011 at Dahej, Gujarat. Both the units are certificated by global accreditations. Aligning with world-class standards, a state-of-art R&D center is located at Thane that adds glory to FBL. Today, it is the only manufacturer and supplier of Vitamin D3 (Cholecalciferol) in South-East Asia and shares the stage with a few manufacturers at the global platform.

Having a dominant presence over fifty countries and 300 global customers, FBL exploits its experience to create a worldwide distribution network for pharmaceuticals, dietary and nutritional supplements, food, feed veterinary and rodenticides.

Prashant Nagre, CEO

Marquee Products & Services Vitamin D3 is the flagship product of FBL and is also its largest portfolio in terms of business. Additionally, it has amassed expertise in integrated biotechnology solutions viz. enzymes as well as an Environmental Solutions business vertical focusing on waste management through a blend of biotechnology and engineering acumen.

utrition and Preventive Health has taken gigantic leaps over the last decade. Emphasizing on creating an environment-friendly, sustainable world, the global nutraceutical industry is set to be a $578.23 billion industry by 2025 as per a report by ASSOCHAM.

N

Vitamin D3 FBL pioneered the use of proprietary technology to manufacture Vitamin D3 in India. It addressed the growing need for its products across a wider range of applications in the food, pharmaceuticals, dietary & nutritional supplements, feed, veterinary and rodenticide segments.

Conceptualized in 1986, Fermenta Biotech Ltd (FBL) is one of the leading entities within the Indian sub-continent that caters to this niche segment. This excerpt illustrates the successful voyage of FBL over the years, along with showcasing the unique products and services while giving a glimpse of an adroit leader - Prashant Nagre, the CEO.

Biotechnology As a pioneer of Penicillin G Amidase (PGA), FBL has commercialized next generation PGA enzyme technologies for Amoxicillin, Ampicillin, Cephalexin, and Cefadroxil.

The company offers improved CAL B Lipase catalysts that can be used for a plethora of applications.

Inception Saga – Going Down the Memory Lane!

FBL, incepted under the auspices of Duphar-Interfran Ltd (now known as DIL Ltd.), is the brainchild of late Mr. Vasant Kumar Datla. Starting the journey from 1986, FBL has stamped its presence across the globe and created countless milestones and continues to march forward. In 1987, FBL’s first manufacturing unit came up in Kullu,

FBL has evolved as a dependable technology-driven partner enjoying customer trust irrespective of project size, phase, and complexity. Embracing innovative technologies have enabled FBL to incorporate the latest, eco-friendly manufacturing practices, along with addressing sectors comprising the pharmaceutical industry, fine chemicals, bio-plastics and cosmetics.

30 |

| APRIL 2019

1 T H E

MOST RECOMMENDED

PHARMA&

L FE SCIENCES SOLUTION PROVIDERS IN 2019

Environmental Solutions FBL, a pioneer in enzyme technologies, offers integrated biotech as well as engineering solutions that address environmental issues. FBL’s tailor-made platform technologies provide unique waste water management and treatment advantages.

Apart from its proprietary bio-product, Fermsept, FBL also offers Engineering Procurement and Construction solutions for a range of applications: encompassing integrated solutions for sewage treatment plants and effluent treatment plants.

Steering the Ship Ahead Prashant Nagre, CEO, has been associated with FBL for almost a decade, leading strategy and overseeing day to day operations of all three business verticals viz. Biotechnology, Pharmaceuticals and Environmental Solutions. He also focuses on further building and developing the various strengths of FBL i.e. Manufacturing, R&D and allied activities. He forms a core member of the product development team and is also responsible for creating and nurturing large business account relationships. Known for his meticulous planning skills, Prashant adds impetus to timely deliveries of products, quality orientation and human resource development within the company.

Awards and Accolades In its endeavor to deliver excellence in services, FBL has been bestowed with numerous awards and recognitions that exemplify its presence as a significant player in the industry. Few of the prized achievements are listed below: • India Pharma Awards 2018 o Excellence in CSR for companies with turnover less than INR 500 Cr. o Pharma International Excellence o Excellence in Export Promotion • Hindustan Times Thane Ratna Award 2019 – Healthcare, Pharma and Biotech Manufacturing • World HRD Congress Awards 2018 o National Best Employer Brands o Business Leader of the Year – Mr. Prashant Nagre o Top 101 HR Minds – Mr. V.K. Raveendranath, General Manager – Human Resources • Pride of Maharashtra Award 2019 for Best CEO of the Year in Manufacturing – Pharmaceuticals – Mr. Prashant Nagre Roadmap to Future As the global biotech industry is witnessing a surge in

APRIL 2019 |

players, competitive markets, and technological advancements, FBL has identified the milestones that it intends to achieve over the next few years. It has broadly classified the goals in three directions:

In the coming years, FBL aims to become a holistic nutraceutical ingredient manufacturer, through developing, manufacturing and commercializing micronutrients required for human and animal nutrition

Product Portfolio Expansion: FBL intends to diversify its portfolio to include a wide range of nutraceutical ingredients such as antioxidants and smart minerals that are microencapsulated for added benefits.

International Collaborations: It continues to make determined efforts to widen its footprint of Vitamin D3 across geographies through engagements established across six continents. To evolve as a key player in the nutraceuticals space, FBL has designed the roadmap to expand its portfolio through distribution agreements, joint ventures, and acquisitions.

Micronutrient Space: FBL has envisaged various synergistic opportunities to create a formidable range of value-added nutritional ingredients, thus widening overall product offerings to cater to the pressing issue of micronutrient deficiency across the globe.

FBL’s Associations Vitamin D Guru: FBL’s public awareness initiative is a digital platform to enhance knowledge about the significance of Vitamin D for health and wellness.

Vitamin Angels: FBL contributes towards Vitamin Angels’ activities in the field of micronutrient deficiency in women and children in developing countries.

National Association for the Blind (NAB): FBL not only contributes towards corneal transplants, squint correction surgeries, educational Braille kits and grant for Diploma in Special Education course, but also integrates NAB’s members with its internal activities for employee engagement.

| 31

Healthcare Predictions

FUTURE PREDICTIONS Of

ELECTRONIC

HEALTH

2019 &

RECORDS,

BEYOND

A About the Author Kumar Subramaniam, Founder & CEO at 75Health Kumar Subramaniam has always believed and used technology as the means to improve the quality of business processes and enhance people's life. He conceptualized the innovative EMR Software with the objective of digitalizing crucial medical records and empowering medical practices to achieve the best care delivery. He leverages technology to achieve business objectives while serving the community better.

32 |

lot of changes and innovations have been occurring in the healthcare sector since the recent decades. Increased personalization in healthcare and increased understanding of patients’ role in achieving success of their own well-being is headed to a tipping point.

Today, in addition to patient care, management of patient experience plays a vital role in the healthcare ecosystem.

With the advent of medical information systems such as the electronic health record software and practice management software, a lot of unprecedented changes have taken place in clinical and administrative

| APRIL 2019

aspects of modern healthcare facilities and physician practices.

The Transition to Electronic Health Records Globally, there has been a wide understanding about the virtues of the electronic health record and how it transforms the way healthcare is provided. Increasing adoption of the EHR is proof enough to emphasize the fact that it has become an integral part of the healthcare setting.

The EHR landscape has had tremendous impact, thanks to the stringent industry standards and regulatory requirements such as HIPAA. Moreover, incentives to providers have also augured well with the increase in EHR adoption.

What Does the Future Hold for the EHR Software?

Although EHRs have been around since long, they are seen to have still a long way to go. As the medical industry switches over from the traditional volume-based reimbursement model to quality-based model, EHRs will be focusing more on value-based care, assisting providers to skillfully manage their patients’ health in the most optimal way.

Understanding the following EHR trends in the coming years will enable practices to be prepared for facing unique needs and delivering the best possible care: • Ease of use and searchability o EHRs will be more easily

APRIL 2019 |

•

•

•

•

searched, organized, and used – enabling full interaction with patients Interoperability and Integration o The ability of EHR Systems to integrate with other health information systems will increase Accessibility o Vendors will ensure that EHRs are more accessible to not only multi-facility networks and hospitals but also to all types of clinical practices regardless of size Standardization o With stricter regulations and standardization of the EHR features and data, overall accuracy and reliability of the EHR System will increase manifold Changing Dynamics o AI and virtual assistants will become more powerful and accessible, making their entry into health IT – this will help mitigate issues, if any, with the EHR Software

The EHR System and Healthcare Delivery Connect Managing patient health records is rendered smooth and effective, thanks to the innovative EHR Software. Using computer software and hardware for the application of data processing ensures easy and accurate storing, sharing, and retrieval of medical information. It also makes it possible to utilize this information for effective communication and information-based decision making.

Networking the computers and communication attributes effectively facilitates efficiently moving critical

health information. This results in increased ability to deliver efficient, better care.

Choosing the Right Fit for Your Practice EHR Software has attained an indispensable position in the healthcare sector. While choosing the EHR solution diligently and perfectly results in providers being facilitated to deliver better care quality and enhance practice efficiency, a wrong selection would lead to significant disruption to regular practice activities and continued difficulty all along the course of use of the software.

As EHRs lend themselves to be customized according to specific practice needs, it is essential to first go through the various features and get complete demo of each solution prior to deciding which one to buy.

With cloud being considered the future of computing and as today’s consumers are more inclined toward using mobile devices, cloud-based mobile EHR is set to become more dominant among EHR Software service providers and practitioners in the future.

In the changing healthcare scenario, EHRs will certainly continue to play the role of the driving force in its evolution. Our goal is transforming the healthcare sector using digital technologies and empowering the healthcare fraternity to raise the bar of quality and efficiency several notches up.

| 33

Top 34 |

Trends to Watch Out in

Pharmaceutical

Pharma Trends

2019 | APRIL 2019

I

ndian pharmaceutical industry is growing with an impressive pace for last couple of years and is expected to be in the top 10 global markets in value terms by 2020. The industry is progressing with a compounded annual growth rate (CAGR) of 15 percent over the last ď€ ve years and is adopting new business models to serve its targeted audience faster, and better. Good economic growth, high burden of diseases, improvement in healthcare infrastructure and increased awareness have tipped to be the reasons behind such optimistic projections.

However, there are many areas on which any pharmaceutical company should look into- such as organ-on-chip, 3D Bio-printing, AI, and Antibiotics Discovery. Ignoring such vital areas can otherwise can hinder the growth prospects of pharmaceutical industry.

APRIL 2019 |

| 35

3D Bio-printing

Organs-on-chips

Every year thousands of people lose their life due to organ failure. Many times even after being nancially capable, people do not receive organs at the right time as there is a wide gap between the growing demand of organs v/s number of registered donors in the industry. Usage 3D bio-printing thus many see as a solution for tackling this critical problem. In bioprinting, experts use patients own living cells to reproduce organs to reduce the risk of rejecting cells.

This further lower the risk of taking immunosuppressant drugs which are needed after organ transplant and many times causes trouble for the patients in terms of loss of appetite, nausea, vomiting, increased hair growth, and hand trembling. Moreover, transplantation using bioprinting only involves only one individual that needs to be operated on and hence, lowers the number of people need to be hospitalized during critical procedures.

Limitations of current planar, animal models and static cell culture system affect the drug discovery process to a larger extent. Many times it leads to increased drug failure rates which even cost pharmaceuticals companies billions of dollars.

Moreover, many human diseases are still not modelled accurately using 'in vitro' process and thus hinder the growth in therapy development.

Shortcomings of these models started a debate in the pharmaceutical vertical to develop a more physiological model relevant to human organs and thus lead to the growth of organs-on-chips.

Many believe that organs made form bio-printing can also be used for drug discovery and testing, tissue engineering, research and study. These are the reasons why pharmaceuticals companies and hospitals are looking towards 3D bio-printing with an array of hope. It is mainly used for the creation and transplantation of several tissues including multilayered skin, heart tissue, cartilaginous structures, bone, vascular grafts, and tracheal splints.

It can also help pharmaceutical companies in reducing overall cost associated with drug manufacturing once get transformed from an experimental stage to a fully functional mode.

Increasing R&D expenditure, availability of venture capital, and government grants are fuelling the growth of 3D bio-printing. It is expected that 3D bioprinting market will reach USD 2.6 billion by 2024.

36 |

Organ-on-chip offers a wide range of applications such as phenotypic screening, diseases modelling, and patient stratication. Scientists believe that organs-on-chips have huge potential to make the drug discovery process efcient and faster as its microchips contain living cells which can mimic processes in the body such as peristalsis, breathing and infection. Such chips are tiny devices that imitate the structure, physiology and function of human organs. Researchers have represented over two dozen organs in on-chip systems, famously includesLung, Heart, Kidney, Artery, Skin. Some are even working to imitate a human-on-chip as well.

While there is a lot of scepticism existed behind organs-on-chips some six to seven years ago, many pharmaceutical companies are now working towards it in a full-edged mode and embraced this concept into their business model as well. Market researchers predicts that organs-on-chip eld which was valued only at $5 million in 2016 will witnessed a meteoric rise in coming years and is expected to reach $170 million by 2023. This industry will grow with a CAGR of 63.2% from 2017 to 2023, researchers predict.

| APRIL 2019

New Antibiotics Discovery

Increased Adoption of AI

Antibiotic resistant bacteria- superbug led to the death of more than 700,000 people all across the world. And, if UK government is to be believed, this number will dramatically jump up to 10 million by 2050; if necessary steps not taken in the arena of new antibiotic discovery. Experts believe irresponsible prescription of antibiotics even for the normal cases, and increased usage of antibiotics in farming accelerating the rate of bacterial mutation, rendering them to resistant to drug with alarming pace.

Developing a drug is a time consuming and expensive task. The current problem of pharmaceutical industry is that nine out of 10 drugs fail to make it to pre-registration stage due to their poor absorption, distribution, metabolism, or excretion (ADME).

On the other hand, antibiotic discovery has been a much ignored area amongst the researchers. Most of the pharmaceutical companies are more inclined towards researching and developing drugs that are more “economically feasible”. This is the reason the last novel antibiotic classes was introduced some thirty years ago.

However, with the growing need to tackle the menace of superbug, beneciary reforms in the legislation and increased investment in antibiotic researchmany organizations are now working day-in day-out to discover new antibiotics.

In 2015, a group of scientists made a breakthrough in the antibiotics vertical with the discovery of Teixobactin, a powerful antibiotics class that has the potential to withstand the development of bacterial resistance against it.

In silico (on a computer) drug design, an innovative technique based on AI can help pharmaceutical companies to reduce such a shocking drug failure ratio. Such techniques allow the mapping of drugs structures and targets that can lead to a more successful drug development without costly scientic development.

Another area of AI which is widely becoming popular is- advanced analytics. Every day thousands of journals and research paper get published on various prominent research institutes. Genius minds from across the globe sweat all through the years to create something concrete but unable to gain any insights form others research concerning to similar set of problems. Analytics has solved such problem. It process vast amount of scientic data and help pharmaceutical companies to develop drug at much faster pace by predicting the properties of new drug candidate in advance. This is the reason many companies now-a-days using AI to predict risks and their drivers to enable preventive maintenance and remediation of the drugs.

In 2018, malacidins, a new family of antibiotics were discovered. However it is currently being in its nascent stage, but one can witness an increasing trend towards discovering new antibiotic class among the scientists community.

- Shruti Jambhale

APRIL 2019 |

| 37

Nucleome Informatics Unraveling the Genomes for a Better Future been regularly working on sequencing of cancer genomes and human exomes. Wildlife and plant genome sequencing and populations genomics is another area of interest where it provides NGS services regularly. The last six years have seen the company assemble 18 plants, 9 animals, 5 insects, and over 100 microbial genomes and analyzed human genome and exome sequencing data (4580 samples by Jan 2019). It was also involved in prestigious sequencing projects like Mango, Pomegranate, Tiger, Indian Wild Dog, Leopard and Insect genome sequencing programs. It also offers cfDNA Sequencing and Cell line genome sequencing services.

The Insightful Minds The company is a resultant of three genius minds coming together.

(From Left to Right)

Dushyant Singh Baghel, MD & CEO Bipin Kumar, Co-founder & VP Abhishek Tripathi, Co-founder & VP

N

ucleome Informatics is well regarded in the Life sciences industry for its expertise in de novo genome sequencing of larger genomes using hybrid assembly approach. Pharma companies and hospitals have been using Nucleome’s genome resequencing, exome sequencing and targeted resequencing services quite often.

Nucleome plays a major role by providing Genomics and Bioinformatics analysis support for scientists working in the field of genomes, transcriptomes, metagenomes, and epigenomes research. Nucleome’s flagship product includes software DrSeq for RNA sequence analysis software, DrSeq Genome Survey and Big Data Decoder server specially designed for NGS analysis. Nucleome also has pipelines for Exome, Metagenome, transcriptome and amplicon datasets developed in-house. It has a variety of projects involving discovery of SNP markers by resequencing of human samples and identifying the complete Genetic makeup of the following organisms like, Buffalo, Pomegranate, Mango, Pigeon Pea, Mosquito, Dhole, Rice varieties, Indian Bengal Tiger, Great Indian Bustard, Eggplant Borer, etc.

Distinguished Services Nucleome has successfully completed many significant plants, animals and microbial de novo genomes and has

38 |

Dushyant Singh Baghel, Founder, MD and CEO hold an MS in Biotechnology from Bharathiar University and executive education in management from Indian School of Business, Hyderabad. He carries twelve years of experience in sequencing and assembly of genomes. A self-motivated person with true qualities of entrepreneurship and leadership, he started the company in the year 2012 with his partners and Co-founders Abhishek Tripathi and Bipin Kumar.

Abhishek Tripathi, VP - R&D and Operations with an MS in Biotechnology has an experience of twelve years in Genomics Industry.

Bipin Kumar, VP - Corporate Sales with an MS in Biotechnology has an experience of thirteen years in Genomics and diagnostics Industry.

With a good understanding of Genomics market in India and their experience, they laid the foundation for Nucleome. Under the leadership of the founders Dushyant Singh Baghel, Bipin Kumar and Abhishek Tripathi, the team has designed and developed software for data analysis, assembled various genomes, completed more than 500 Genome and Transcriptome projects in a span of 6 years. Currently Nucleome is being considered as India’s fastest growing genomics and bioinformatics solution provider.

| APRIL 2019

1 T H E

MOST RECOMMENDED

PHARMA&

L FE SCIENCES SOLUTION PROVIDERS IN 2019

Hard Work is all it takes to Succeed Nucleome has invested its entire seed funding in building a well-equipped laboratory with sophisticated wet lab instruments and servers like BigData Decoder which are specially designed for next generation sequencing data analysis along with NGS analysis pipelines on online cloud servers like Google genomics, Amazon Web Server and DNA nexus.

• It has successfully completed various projects in association with various International organizations like CNRGV (France), Fasteris SA (Switzerland), Koppert Biological Systems (The Netherlands), Cold Spring Harbor Laboratory (USA), McDonnell Genome Institute, (USA), University of California (USA), Yale University (USA), New York Genome Center (USA), Washington University(USA), The Queensland Alliance for Agriculture and Food Innovation(Australia) and Indian institutes like CCMB, CIBA, IHBT, NRCP, NRCPB, ILS and NDDB. Nucleome has also built a sound association with all the major institutes under ICAR, CSIR, DBT and various hospitals including Tata Memorial Hospital Mumbai and private organisations like ITC and Beej Sheetal Seeds.

Nucleome was awarded ‘India’s 20 Most Promising Pharma & Life Science Technology Solution Provider Companies 2016’ by a leading magazine.

Using Nucleome’s services researchers have published several Research Papers.

Paper in the field of Animal Genomics: • The Cuon Enigma: Genome survey and comparative genomics of the endangered Dhole 1 (Cuon alpinus) in bioRxiv • High coverage genome sequencing and identification of genomic variants in Bengal tiger (Panthera tigris tigris) in bioRxiv • Genome Plasticity in Cultured Leishmania donovani: Comparison of Early and Late Passages in Frontiers in Microbiology • RNA-Seq Revealed Expression of Many Novel Genes Associated With Leishmania do no vani Persistence and clearance in the Host Macrophage in Frontiers in Cellular and Infection Microbiology Papers in the field of Agri Genomics: • Analysis of DNA methylome and transcriptome profiling following Gibberellin A3 (GA3) foliar application in Nicotiana tabacum L. in Indian Journal of Plant Physiology • Identification of candidate pathogenicity determinants of APRIL 2019 |

•

•

Rhizoctonia Company’s expertise solani AG1-IA, which causes lies in Sequencing sheath blight and Analysis of de disease in rice in novo genome using Current Genetics hybrid assembly of Springer approach, Nature Transcriptome, Alterations in rice and genome chloroplast resequencing data integrity, photosynthesis and metabolome associated with pathogenesis of Rhizoctonia solani in Scientific Reports Sequencing, Denovo Assembly, Functional Annotation and Analysis of Phyllanthus amarus Leaf Transcriptome Using the Illumina Platform in Frontiers in Plant Science Analysis of high iron rice lines reveals new miRNAs that target iron transporters in roots in Journal of Experimental Botany

Lapping up the Opportunities The Pharma and life science industry is bustling with ideas and applications. The increasing application of genomics in biotech and pharmaceutical research and development has created a huge commercial market for sequencing and bioinformatics worldwide. The explosive growth of biological techniques necessitates the acquisition, processing, analysis, and integration of the data. These immense amounts of data are generated by the experiments as diverse as genomics, cloning, expression analysis, genotyping, cellular analysis and others. Many young entrepreneurs are looking at it as an opportunity for new startups. The founders advise them saying “Dare to dream…..Follow your dream….Live your dream…..Strive hard to achieve your dream.”

For a Better Future Nucleome aims at a healthier future through revolutionary genetic analysis solutions. It is committed to generating rapid, appropriate and high-quality results which can create a great difference in research projects.

Nucleome’s focus has always been in the field of Plant, Animal and Human Genomics and is planning to strengthen its position in this field. It has planned to raise its SeriesA funding to expand its infrastructure by building India’s largest genomics and supercomputing bioinformatics facility. It aims to fund and propel its Population genomics program to sequence 10,000 human genomes and 100,000 exomes of various cancer and diabetics patients in India. | 39